Sign in
Taking peoplePhase 2

Comprehensive Ambulatory Antibiotics for the Treatment of Congenital Syphilis

Key facts

Who runs it
London School of Hygiene and Tropical Medicine
Where
Indonesia, Malawi, and South Africa3 sites in 3 countriesChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
90 people, planned
Started
4 May 2026
Expected to end
30 Jun 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Linezolid (LZD)
  • Amoxicillin
  • Benzathine Penicillin G
Record updated
22 October 2026

Who can take part

Age
0 days to 7 days
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Infants at risk of congenital syphilis at birth defined as:; an infant born to a mother who tests positive for syphilis in pregnancy using registered and licensed locally-available diagnostic tests for example but not limited to a Treponemal rapid POCT, an RPR or both; AND; the mother is untreated in the current pregnancy defined as:; she tested positive at antenatal care and received no treatment OR ii. she was never tested during antenatal care OR iii. she tested negative at antenatal care and positive on re-testing at delivery; OR c. the mother is inadequately treated in the current pregnancy defined as:; Having received a non-penicillin based treatment regimen; and/or ii. Does not have documentation of 3 doses of IM Benzathine Penicillin, given 7-10 days apart, with the last dose given > 30 days prior to delivery OR b. The mother was adequately treated in the current pregnancy BUT considers herself at risk of re-infection following a midwife delivered explanation of risk (partner treatment, multiple partners etc)
  • Infants who are asymptomatic for a diagnosis of congenital syphilis following application of a clinical proforma by the study team (Appendix 1)
  • Infants who are less than <= 7 days of life AND with a post-menstrual age (PMA) of 34-42 weeks (Appendix 2)
  • Infants who are tolerating enteral feeds, including if they are being administered by an NG tube

Who cannot take part

  • 1. The infant's clinical condition at birth or prior to randomisation requires ongoing (> 48 hours) treatment with antibiotics with the potential for anti-treponemal activity i.e. B-lactams, Cephalosporins, Carbapenems
  • They have a birthweight <2kg 3. They are nil by mouth. 4. They have a life-limiting congenital anomaly

This trial is currently available in Indonesia, Malawi, and South Africa.

It has sites in 3 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

CARES-1 is a randomised, open-label, phase II pharmacokinetic (PK) and safety study of ambulatory antibiotics for the treatment of neonates with "all-risk" asymptomatic congenital syphilis.

The 3 groups in the trial

  • Oral LinezolidTreatment being tested

    10 day course of Linezolid twice a day

    Treatment: Linezolid (LZD)

  • Oral AmoxicillinTreatment being tested

    10 day course of Amoxicillin twice a day

    Treatment: Amoxicillin

  • IM Benzathine penicillinExisting treatment, for comparison

    Single IM dose of IM Benzathine penicillin

    Treatment: Benzathine Penicillin G

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
22 October 2026